Sentien Biotechnologies, Inc. is a privately owned, late preclinical stage company developing novel approaches to cell therapy.
Sentien's lead product combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device, allowing for controlled, sustained delivery of MSC secreted factors. The product is being tested to treat systemic inflammatory diseases where MSCs can condition blood continuously during an acute illness.
- Brian Miller, MS/MBA CEO, Co-Founder
- Biju Parekkadan, PhD Scientific Co-Founder